key: cord-0842680-z650a1oe authors: Troya, Jesús; Bastard, Paul; Planas-Serra, Laura; Ryan, Pablo; Ruiz, Montse; de Carranza, María; Torres, Juan; Martínez, Amalia; Abel, Laurent; Casanova, Jean-Laurent; Pujol, Aurora title: Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain date: 2021-04-13 journal: J Clin Immunol DOI: 10.1007/s10875-021-01036-0 sha: 68278df90427f067815d5453abe0b51f34dbcf6b doc_id: 842680 cord_uid: z650a1oe BACKGROUND: In a recent study, autoantibodies neutralizing type I interferons (IFNs) were present in at least 10% of cases of critical COVID-19 pneumonia. These autoantibodies neutralized most type I IFNs but rarely IFN-beta. OBJECTIVES: We aimed to define the prevalence of autoantibodies neutralizing type I IFN in a cohort of patients with severe COVID-19 pneumonia treated with IFN-beta-1b during hospitalization and to analyze their impact on various clinical variables and outcomes. METHODS: We analyzed stored serum/plasma samples and clinical data of COVID-19 patients treated subcutaneously with IFN-beta-1b from March to May 2020, at the Infanta Leonor University Hospital in Madrid, Spain. RESULTS: The cohort comprised 47 COVID-19 patients with severe pneumonia, 16 of whom (34%) had a critical progression requiring ICU admission. The median age was 71 years, with 28 men (58.6%). Type I IFN-alpha- and omega-neutralizing autoantibodies were found in 5 of 47 patients with severe pneumonia or critical disease (10.6%), while they were not found in any of the 118 asymptomatic controls (p = 0.0016). The autoantibodies did not neutralize IFN-beta. No demographic, comorbidity, or clinical differences were seen between individuals with or without autoantibodies. We found a significant correlation between the presence of neutralizing autoantibodies and higher C-reactive protein levels (p = 5.10e(−03)) and lower lymphocyte counts (p = 1.80e(−02)). No significant association with response to IFN-beta-1b therapy (p = 0.34) was found. Survival analysis suggested that neutralizing autoantibodies may increase the risk of death (4/5, 80% vs 12/42, 28.5%). CONCLUSION: Autoantibodies neutralizing type I IFN underlie severe/critical COVID-19 stages in at least 10% of cases, correlate with increased C-RP and lower lymphocyte counts, and confer a trend towards increased risk of death. Subcutaneous IFN-beta treatment of hospitalized patients did not seem to improve clinical outcome. Studies of earlier, ambulatory IFN-beta treatment are warranted. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10875-021-01036-0. In December 2019, infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, China. One year later, as of December 22, 2020, it has caused over 79 million reported cases and at least 1.7 million deaths globally [1] . A striking feature is the vast interindividual clinical variability in the course of infection. The vast majority of infected individuals remain asymptomatic or develop mild, self-healing, ambulatory disease of the upper respiratory tract. In approximately 3% of subjects, SARS-CoV-2 infection results in pneumonia, which in approximately 0.3% of subjects evolves into acute respiratory distress syndrome (ARDS) with systemic inflammation [2] . The identification of the determinants of COVID-19 severe pneumonia could change the current treatment and prognosis of the disease. The contribution of inborn errors of immunity to the determinism of severe infectious diseases is well established, particularly for viral infections, such as severe influenza pneumonia [3, 4] . Autoimmune phenocopies of inborn errors of cytokines, with neutralizing autoantibodies to cytokines, are also well known [5] . In this context, two studies of the COVID Human Genetic Effort consortium have recently reported that in a cohort of nearly 1000 patients with life-threatening COVID-19 pneumonia, at least 10% showed neutralizing autoantibodies against type I interferons (IFNs) [6] , while another 3.5% carried rare deleterious variants in 8 genes governing TLR3-and IRF7-dependent type I IFN immunity to influenza virus [7] . These data provided evidence that defective type I IFN immunity could underlie life-threatening COVID-19 pneumonia in a significant proportion of cases [8] . The 17 individual type I IFNs are part of both intrinsic and innate immunity. They are known to increase cell defenses in response to various viruses, blocking viral spread [9] . Insufficient type I IFN immunity during the first days of infection with SARS-CoV-2 may result in viral spread to the lungs and via the bloodstream. This spread may in turn unleash excessive inflammation, including a cytokine storm, when leukocytes are recruited to infected tissues. Defects in type I IFN immunity may therefore explain why some infected subjects develop a severe pneumonia, and progress to an acute respiratory distress syndrome (ARDS), systemic inflammation, and critical disease, requiring admission to the intensive care unit (ICU). Importantly, autoantibodies to type I IFN neutralize most but not all individual IFNs. They typically neutralize the 13 IFN-alpha proteins and a single IFNomega but rarely neutralize IFN-beta, IFN-kappa, and IFN-epsilon [6] . The detailed epidemiological and clinical characteristics of patients with autoantibodies to type I IFNs, as well as their response to type I IFN therapy, have not been reported. We set out to study patients from a single hospital in Madrid, Spain, one of the global epicenters of COVID-19 during the first wave. We analyzed the presence of autoantibodies against type I IFNs and compared patients with severe pneumonia with and without these autoantibodies, in terms of clinical features and outcome, as well as responses to subcutaneous IFN-beta therapy during hospitalization. Indeed, in the context of emerging SARS-CoV2 infection, IFN-beta was administered to severe hospitalized patients in the first months of the pandemic, alone or combined with other drugs, due to the unavailability of a specific treatment, and their unspecific antiviral effects [9] . Interferons, mainly IFN-beta, have shown to have in vitro activity against SARS-CoV and MERS-CoV [10, 11] and to reduce the mortality rate and need for intensive respiratory support in hospitalized patients [12] . Our sample consisted of 47 hospitalized clinically severe COVID-19 patients with pneumonia and oxygen support who were treated subcutaneously with IFN-beta-1b from March to May 2020. We tested for the presence of autoantibodies against IFN, and analyzed the possible impact of these autoantibodies in different clinical variables and the response to IFN-beta, in terms of bad prognosis or mortality. We studied data from hospitalized adult patients with COVID-19 pneumonia treated subcutaneously with recombinant IFN-beta-1b (Betaferon) during admission at the Infanta Leonor University Hospital in Madrid, Spain, from the first wave of the pandemic (March to May 2020), in a retrospective manner. Based on the local treatment protocol at that time, when no drug had yet been proven efficacious, IFN-beta-1b was administered only to patients with severe respiratory failure and lack of initial response to the standard treatment (lopinavir/ritonavir, hydroxychloroquine, azithromycin). We initially selected, from a cohort of 1549 COVID-19 patients admitted to the hospital [13] , 47 clinically severe patients who were treated with IFN-beta-1b (250 μg every 48 h for up to 14 days) and who had an available plasma sample collected prospectively during hospitalization and stored in the hospital sample collection; this criterion was mandatory to guarantee the possibility to perform a test to determine the presence of anti-IFN autoantibodies. All 47 patients were considered clinically severe at admission following the US National Institutes of Health (NIH) classification [14] . The patients presented SpO 2 < 94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO 2 /FiO 2 ) <300 mmHg, respiratory frequency > 30 breaths/min, or lung infiltrates >50%. Patients who progressed to an ARDS were defined as critical following the NIH guidelines [14] , with 200 mmHg 65 years of age with subcutaneous IFN-beta might be considered, as this shortterm treatment appears to be safe, with side-effects mostly resolving within 3 days after drug initiation, and no severe adverse events or related deaths reported [25] . WHO. Coronavirus disease 2019 (COVID-19). Available at COVID-19: consider cytokine storm syndromes and immunosuppression Host genetics of severe influenza: from mouse Mx1 to human IRF7 Human inborn errors of immunity to herpes viruses Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19 Life-threatening COVID-19: defective interferons unleash excessive inflammation Decoding type I and III interferon signalling during viral infection In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study Clinical Spectrum of SARS-CoV-2 Infection Research electronic data capture (REDCap) a metadata-driven methodology and workflow process for providing translational research informatics support Combination of tocilizumab and steroids to improve mortality in patients with severe COVID-19 infection: a Spanish, multicenter, cohort study Early clinical outcomes with tocilizumab for severe Covid-19: a two-center retrospective study Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a metaanalysis with 55 studies and 10014 cases Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study C-reactive protein concentration as a risk predictor of mortality in intensive care unit: a multicenter, prospective, observational study Selection of an optimal combination panel to better triage COVID-19 hospitalized patients Elevated serum ferritin level effectively discriminates severity illness and liver injury of coronavirus disease 2019 pneumonia Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator A systematic review and metaanalysis of published research data on COVID-19 infection fatality rates Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic Interferon-β therapy in a patient with Incontinentia Pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2 Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Acknowledgements We thank all the study participants, who donated blood, and all the clinicians who attended COVID-19 patients at Infanta Leonor University Hospital. We thank the members of both branches of the Laboratory of Human Genetics of Infectious Diseases: Adrian Gervais, Jérémie Rosain, Quentin Phillipot, Tom Le Voyer, Mélanie Migaud, Lazaro Lorenzo-Diaz, Yelena Nemirovskaya, Qian Zhang, Anne Puel, Emmanuelle Jouanguy, Shen-Ying Zhang, and Aurélie Cobat for their help and fruitful discussions. The online version contains supplementary material available at https://doi.org/10.1007/s10875-021-01036-0.